Argenx's Vyvgart Hytrulo Shot Gains Second FDA Approval for CIDP with Halozyme's ENHANZE

Jun 21, 2024, 09:10 PM

Argenx's Vyvgart Hytrulo shot has received its second US FDA approval to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare nervous system disorder. This approval marks a significant milestone for the biotechnology firm, which has faced a series of setbacks. The Vyvgart Hytrulo shot is co-formulated with Halozyme's ENHANZE technology. This label expansion into CIDP adds to Argenx's growth prospects ahead of more clinical milestones anticipated in 2024.